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Heart failure (HF) is driven by the interplay between
regulatory transcription factors and dynamic alter-
ations in chromatin structure. Pathologic gene trans-
activation in HF is associated with recruitment of
histone acetyl-transferases and local chromatin
hyperacetylation. We therefore assessed the role of
acetyl-lysine reader proteins, or bromodomains, in
HF. Using a chemical genetic approach, we establish
a central role for BET family bromodomain proteins in
gene control during HF pathogenesis. BET inhibition
potently suppresses cardiomyocyte hypertrophy
in vitro and pathologic cardiac remodeling in vivo.
Integrative transcriptional and epigenomic analyses
reveal that BET proteins function mechanistically as
pause-release factors critical to expression of genes
that are central to HF pathogenesis and relevant to
the pathobiology of failing human hearts. This study
implicates epigenetic readers as essential effectors
of transcriptional pause release during HF pathogen-
esis and identifies BET coactivator proteins as thera-
peutic targets in the heart.
INTRODUCTION
Heart failure (HF) is a leading cause of healthcare expenditures,
hospitalization, and mortality in modern society (Hill and Olson,
2008; Roger et al., 2012). HF occurs when the heart is unable
tomaintain organ perfusion at a level sufficient tomeet tissue de-
mand and results in fatigue, breathlessness, multiorgan dysfunc-
tion, and early death. Existing pharmacotherapies for individuals
afflicted with HF, such as b adrenergic receptor antagonists andinhibitors of the renin-angiotensin system, generally target
neurohormonal signaling pathways. While such therapies have
improved survival in HF patients, residual morbidity andmortality
remain unacceptably high (Roger et al., 2012). In light of this un-
met clinical need, the elucidation of novel mechanisms involved
in HF pathogenesis holds the promise of identifying new thera-
pies for this prevalent and deadly disease.
In response to diverse hemodynamic and neurohormonal in-
sults, the heart undergoes pathologic remodeling, a process
characterized by increased cardiomyocyte (CM) volume (hyper-
trophy), interstitial fibrosis, inflammatory pathway activation, and
cellular dysfunction culminating in contractile failure (Hill and
Olson, 2008; Sano et al., 2002; van Berlo et al., 2013). The path-
ologic nature of this process has been validated in large epidemi-
ologic studies, which demonstrate that the presence of chronic
cardiac hypertrophy is a robust predictor of subsequent HF
and death (Hill and Olson, 2008; Levy et al., 1990). Although
hypertrophic remodeling may provide short-term adaptation to
pathologic stress, sustained activation of this process is mal-
adaptive and drives disease progression (Hill and Olson, 2008).
Studies over the past decade have clearly demonstrated that
inhibition of specific prohypertrophic signaling effectors exerts
cardioprotective effects even in the face of persistent stress.
Together, these data provide a cogent rationale that targeting
the hypertrophic process itself can be beneficial without
compromising contractile performance (Hill and Olson, 2008;
van Berlo et al., 2013).
Hemodynamic and neurohormonal stressors activate a
network of cardiac signal transduction cascades that ultimately
converge on a defined set of transcription factors (TFs), which
control the cellular state of the CM (Hill and Olson, 2008; Lee
and Young, 2013; van Berlo et al., 2013). Studies in animal
models have implicated several master TFs that drive HF pro-
gression (e.g., NFAT, GATA4, NFkB, MEF2, c-Myc) via induction
of pathologic gene expression programs that weaken cardiacCell 154, 569–582, August 1, 2013 ª2013 Elsevier Inc. 569
performance (Hill and Olson, 2008; Maier et al., 2012; van Berlo
et al., 2011; Zhong et al., 2006). In addition to stimulus-coupled
activation of DNA-binding proteins, changes in cell state occur
through an interplay between these master regulatory TFs and
changes in chromatin structure (Lee and Young, 2013). Notably,
stress pathways activated in HF are associated with dynamic re-
modeling of chromatin (McKinsey and Olson, 2005; Sayed et al.,
2013), including global changes in histone acetylation and DNA
methylation. As alterations in higher-order chromatin structure
modulate the net output of multiple, simultaneously activated
transcriptional networks (Lee and Young, 2013; Schreiber and
Bernstein, 2002), manipulation of cardiac gene control via
targeting of chromatin-dependent signal transduction repre-
sents a potentially powerful therapeutic approach to abrogate
pathologic gene expression and HF progression.
Transcriptional activation is associated with local N-ε-acetyla-
tion of lysine sidechains on the unstructured amino-terminal tail
of histone proteins (Schreiber and Bernstein, 2002). Dynamic
positioning of acetyl-lysine (Kac) arises from the interplay of
so-called epigenetic ‘‘writers’’ (histone acetyltransferases
or HATs) and epigenetic ‘‘erasers’’ (histone deacetylases or
HDACs). Context-specific recognition of Kac at regions of
actively transcribed euchromatin is mediated by epigenetic
‘‘reader’’ proteins possessing a Kac-recognition module or bro-
modomain (Filippakopoulos et al., 2012). Molecular recognition
of Kac by bromodomain-containing proteins serves to increase
the effective molarity of transcriptional complexes promoting
chromatin remodeling, transcriptional initiation, and elongation
(Dawson et al., 2012). Elegant studies over the past decade
have implicated both epigenetic writers (e.g., EP300) (Wei
et al., 2008) and erasers (e.g., HDACs) (Montgomery et al.,
2007; Trivedi et al., 2007; Zhang et al., 2002) in cardiac develop-
ment and disease. In contrast, little is known about epigenetic
readers in cardiac biology.
Members of the bromodomain and extraterminal (BET) family
of bromodomain-containing reader proteins (BRD2, BRD3,
BRD4, and testis-specific BRDT) associate with acetylated chro-
matin and facilitate transcriptional activation by recruitment of
coregulatory complexes such as mediator (Jiang et al., 1998)
and the positive transcription elongation factor b (P-TEFb) (Har-
greaves et al., 2009; Jang et al., 2005; Yang et al., 2005).
Recently, we developed a first-in-class potent, selective bromo-
domain inhibitor, JQ1, which displaces BET bromodomains from
chromatin resulting in suppression of downstream signaling
events to RNA polymerase II (Pol II) (Delmore et al., 2011; Filippa-
kopoulos et al., 2010). We and others have utilized this chemical
genetic tool to probe BET function in a number of developmental
and disease contexts, such as cancer (Delmore et al., 2011; Fil-
ippakopoulos et al., 2010), HIV infection (Banerjee et al., 2012),
and spermatogenesis (Matzuk et al., 2012). The role of BET bro-
modomain proteins in the heart remains unknown.
In this study, we report that BETs are critical effectors of path-
ologic cardiac remodeling via their ability to coactivate defined
stress-induced transcriptional programs in the heart. An impor-
tant mechanism by which BETs drive pathologic gene induction
is via their ability to promote transcriptional pause release and
elongation, thereby coactivating multiple master TFs known to
initiate and promote HF. The elucidation of BET function in the570 Cell 154, 569–582, August 1, 2013 ª2013 Elsevier Inc.heart implicates epigenetic reader proteins in cardiac biology
and HF pathogenesis. Moreover, use of chemical biology to spe-
cifically probe the role of BET bromodomain-containing proteins
in the myocardium suggests that targeted manipulation of chro-
matin-based signal transduction might be harnessed for thera-
peutic gain in heart disease.
RESULTS
BET Bromodomains Are Cell-Autonomous Regulators
of Pathologic Cardiomyocyte Hypertrophy In Vitro
Because pathologic cardiac hypertrophy features coordinate
transcriptional activation of numerous master regulatory TFs,
we hypothesized that BET bromodomains would function as
coactivator proteins in this disease process. We first assessed
the expression patterns of BETs in the heart. Analysis of neonatal
rat ventricular cardiomyocytes (NRVM) and adult mouse ventric-
ular tissue revealed that Brd2, Brd3, and Brd4 are transcribed,
with Brd4 emerging as most highly expressed (Figures S1A
and S1B available online). Western blots in NRVM, mouse heart
tissue, and human heart tissue confirmed abundant BRD4
expression (Figure S1C) and immunofluorescence staining of
NRVM demonstrated BRD4 to be nuclear localized (Figure S1D).
First, using a chemical biology approach, we leveraged the vali-
dated small-molecule probe of BET bromodomain function, JQ1
(Figure 1A), in the established NRVM model in vitro (Simpson
et al., 1982). Nanomolar doses of JQ1 significantly blocked
phenylephrine (PE)-mediated cellular hypertrophy (Figure 1B)
and pathologic gene induction (Figure 1C). In a similar manner,
knockdown of Brd4 in NRVM (Figure S1E) also attenuated PE-
mediated hypertrophic growth (Figure 1D) and pathologic gene
induction (Figure 1E). We next assessed a number of structurally
dissimilar BET inhibitors (I-BET, I-BET-151, RVX-208, and PFI-1;
chemical structures shown in Figure S1F) for their ability to inhibit
CM hypertrophy. At equimolar doses, we found that inhibition of
agonist-induced CM hypertrophy was indeed a class effect of
BET inhibitors, with the relative potency of these compounds
correlating with their known IC50 against BRD4 (Filippakopoulos
et al., 2010). Together, these data implicate BET bromodomain
proteins as putative cell-autonomous regulators of pathologic
CM hypertrophy and identify potent antihypertrophic effects of
the small-molecule BET inhibitor JQ1 in vitro.
BETs Are Required for Induction of a Pathologic Gene
Expression Program in Cardiomyocytes
To determine the transcriptional effects of BET bromodomain
inhibition during CM hypertrophy, we performed gene expres-
sion profiling (GEP) studies in cultured NRVM at baseline and af-
ter PE stimulation (1.5, 6, and 48 hr) in the presence or absence
of JQ1. These three time points capture induction of early
response genes such as c-Myc (Zhong et al., 2006), as well as
the late hypertrophic expression program. Assessment of differ-
entially expressed transcripts revealed three major clusters:
genes that were PE inducible and suppressed by JQ1, genes
that were PE inducible and unaffected by JQ1, and genes that
were PE suppressed and unaffected by JQ1. A heatmap of
genes selected based on the highest magnitude of PE-mediated
change illustrates each of these clusters (Figure 2A; full list of
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Figure 1. BET Bromodomain Inhibition Blocks CM Hypertrophy In Vitro
(A) (+)-JQ1 structure.
(B) Representative image of NRVM treated ±JQ1 (250 nM) and PE (100 mM) for 48 hr with cell area quantification. *p < 0.05 versus veh -PE. **p < 0.05 versus JQ1
-PE. #p < 0.05 versus veh +PE.
(C) qRT-PCR of NRVM treated with JQ1 (500 nM) and PE (100 mM, 48 hr, n = 4). #p < 0.05 versus veh, *p < 0.05 versus PE.
(D) Representative image of NRVM infected with Ad-sh-Brd4 or sh-cntrl treated ±PE (100 mM, 48 hr) with cell area quantification. *p < 0.05 versus sh-cntrl -PE.
**p < 0.05 versus sh-Brd4 -PE. #p < 0.05 versus sh-cntrl +PE.
(E) qRT-PCR of NRVM during Brd4 knockdown ±PE (100 mM, 48 hr, n = 4). #p < 0.05 versus sh-cntrl, *p < 0.05 versus sh-cntrl+PE.
(F) Cell area of NRVM treated with indicated BET inhibitors (500 nM) ±PE (100 mM, 48 hr). *p < 0.05 versus –PE control for indicated compound. #p < 0.05 versus
veh +PE. Scale bar, 30 mM. Data shown as mean ± SEM.
See also Figure S1.
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differential transcripts provided in Table S1). Global analysis of
GEPs revealed that PE stimulation resulted in the cumulative in-
duction of over 450 genes and that JQ1 abrogated induction of a
substantial subset of PE-inducible genes. Statistically significant
transcriptional effects were evident as early as 1.5 hr and
increased over time (Figures 2B and 2C), consistent with the
emerging role of BETs as coactivators of inducible gene expres-
sion programs (Nicodeme et al., 2010). Functional pathway anal-
ysis of PE-inducible transcripts that were suppressed by JQ1
revealed that BETs facilitate expression of a host of biological
processes known to be involved in pathologic CM activation,
including cytoskeletal reorganization, extracellular matrix pro-
duction, cell-cycle reentry, paracrine/autocrine stimulation of
cellular growth, and proinflammatory signaling (Figure 2D)
(Song et al., 2012). Using the prohypertrophic cytokine Il6 as a
representative target (Figure 2C), we confirmed by qRT-PCR
that JQ1 significantly attenuated PE-mediated induction (Fig-
ure 2E). Activity of BETs during pathologic stress was not due
to PE-mediated increases in BET expression (Figure S2). Chro-
matin immunoprecipitation (ChIP) studies demonstrated BRD4
occupancy at the Il6 locus and an increase in BRD4 enrichment
after 90 min of PE stimulation that was blocked by BET inhibition
(Figure 2F). Interestingly, BET bromodomain inhibition did not
affect PE-mediated induction ofMyc (Figure 2G), an established
transcriptional driver of pathologic cardiac hypertrophy (Zhong
et al., 2006). Prior studies from our laboratory and others have
implicated BET bromodomains in neoplastic MYC transcription
in hematopoietic tumors (Delmore et al., 2011; Zuber et al.,
2011). Collectively, these in vitro data (Figures 1 and 2) demon-
strate that BET bromodomain-containing proteins regulate CM
hypertrophy in a cell-autonomous manner via coactivation of a
broad but specific transcriptional program.
BET Bromodomain Inhibition Arrests Pathologic
Hypertrophy and Heart Failure In Vivo
Given these observations in cultured CMs, we hypothesized that
BETs might regulate pathologic cardiac remodeling in the intact
organism. We leveraged the favorable therapeutic index of JQ1,
which has previously been shown to potently inhibit BET bromo-
domain function in adult mice without significant toxicity when
administered chronically at 50 mg/kg/day (Filippakopoulos
et al., 2010). Independently, we confirmed the lack of overt
toxicity by treating mice with JQ1 for 2–3 weeks, observing no
effect on endurance exercise capacity (Figure S3A), a metric of
global cardiometabolic health. For in vivo studies, we first used
transverse aortic constriction (TAC), a thoroughly characterizedFigure 2. BET Regulated Transcriptional Programs during CM Hypertr
(A) Selected heatmap of differentially expressed (DE) transcripts. NRVM treated
(B) Global analysis of DE transcripts showing induction of genes by PE with time
(C) Volcano plot showing fold change (x axis) effect of PE+JQ1 versus PE+vehicl
(shades of red). Progression from lighter to darker shading represents increasing
(D) Functional pathway analysis (DAVID) of PE-induced genes that were JQ1-rev
(E) Il6 qRT-PCR in NRVM treated with JQ1 (500 nM) and PE (100 mM, n = 4). *p <
(F) BRD4ChIP-qPCR in NRVM treatedwith JQ1 (500 nM) and PE (100 mM) for 90m
veh, #p < 0.05 versus PE.
(G) Myc qRT-PCR in NRVM treated with JQ1 (500 nM) and PE (100 mM, n = 4). *
See also Figure S2 and Table S1.model of cardiac pressure overload, which provides focal hemo-
dynamic stress to the heart and recapitulates several cardinal
aspects of pathologic hypertrophy and HF in humans (Rockman
et al., 1991). In our hands, adult mice subject to TAC develop
concentric left ventricular hypertrophy (LVH) by 7–10 days and
progress to advanced HF after 3–4 weeks.
We performed TAC or sham surgery, followed by administra-
tion of JQ1 (50 mg/kg/day versus vehicle control) beginning
1.5 days after initiation of TAC (Figure 3A). Serial echocardiogra-
phy showed that JQ1 protected against TAC-mediated LV sys-
tolic dysfunction, cavity dilation, and wall thickening, with effects
that were sustained out to 4 weeks (Figures 3B–3D and S3B;
Movies S1 and S2). JQ1 treatment also inhibited pathologic car-
diomegaly (Figure 3E; representative photos in Figure 3F), pul-
monary congestion (Figure 3G), and myocardial expression of
canonical hypertrophic marker genes (Figure 3H) after TAC.
JQ1 was well tolerated, as evidenced by normal activity (Movies
S3 and S4) and the lack of significant mortality or weight loss
compared to vehicle-treated mice (data not shown). In addition,
JQ1 had no adverse effect on LV structure or function in sham-
treated mice (Figures 3E, 3F, and S3B). Importantly, JQ1 does
not affect systemic blood pressure (Figure S3C). Furthermore,
the protective effects of JQ1 in the TAC model were not associ-
ated with differences in the pressure gradient across the aortic
constriction (Figure S3D).
In addition to hemodynamic stress, excessive neurohormonal
activation is also a central driver of pathologic cardiac hypertro-
phy (Hill and Olson, 2008; van Berlo et al., 2013). Therefore, we
next assessedwhether JQ1 could ameliorate pathology in a sec-
ond mouse model of neurohormonally mediated cardiac hyper-
trophy. Mice were implanted with osmotic minipumps delivering
phenylephrine (PE, 75 mg/kg/day versus saline) followed by JQ1
or vehicle administration beginning 1.5 days after minipump
installation. This infusion protocol produces robust concentric
LVH in 2–3 weeks but does not cause significant LV cavity dila-
tion or depression of LV systolic function in wild-type mice.
Concordant with our TAC results above, JQ1 potently sup-
pressed the development of pathologic cardiac hypertrophy dur-
ing chronic PE infusion, without any compromise in LV systolic
function (Figure 3I).
In addition to favorable effects on cardiac function, we as-
sessed whether JQ1 also ameliorated cardinal histopathologic
features of HF in vivo. Analysis of mouse heart tissue demon-
strated that JQ1 significantly attenuated the development of
CM hypertrophy (Figure 4A), myocardial fibrosis (Figure 4B),
apoptotic cell death (Figure 4C), and capillary rarefactionophy In Vitro
with 500 nM JQ1, 100 mM PE.
(red) and progressive reversal of PE-mediated gene induction by JQ1 (blue).
e (shades of blue) on all genes upregulated at any time point by PE versus veh
time (1.5, 6, and 48 hr).
ersed. FDR < 5% considered statistically significant.
0.05 versus veh, #p < 0.05 versus PE.
in. Target and nontarget (4 kb region) primers depicted. n = 3, *p < 0.05 versus
p < 0.05 versus veh, #p < 0.05 versus PE. Data shown as mean ± SEM.
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Figure 3. BET Bromodomain Inhibition with JQ1 Potently Attenuates Pathologic Cardiac Hypertrophy and HF In Vivo
(A) Experimental protocol.
(B) Echocardiographic parameters during TAC (n = 7). LVIDd is LV end diastolic area, (IVS + PW)d is sum thickness of the interventricular septum and posterior LV
wall at end diastole. *p < 0.05 versus veh TAC.
(C) Representative M-mode tracings and (D) end-diastolic 2D images at 4 weeks TAC. Scale bar, 3 mm.
(E) Heart/body weight (HW/BW) ratios, 4 weeks. *p < 0.05 versus sham veh. #p < 0.05 versus TAC veh. **p < 0.05 versus sham JQ1.
(F) Representative photos of freshly excised whole hearts. Scale bar, 3 mm.
(G) Lung/body weight (LW/BW) ratios, 4 weeks TAC (n = 7 TAC, n = 5 sham). *p < 0.05 versus sham veh. #p < 0.05 versus TAC veh.
(H) qRT-PCR in mouse hearts (n = 5–7). *p < 0.05 versus sham veh. #p < 0.05 versus TAC veh.
(I) PE infusion (75 mg/kg/day) and JQ1 administration (n = 7 PE, n = 5 normal saline). *p < 0.05 versus NS veh. **p < 0.05 versus PE veh. Data shown as mean ±
SEM.
See also Figure S3 and Movies S1, S2, S3, and S4.
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Figure 4. BET Bromodomain Inhibition Attenuates Cardinal Histopathologic Features of HF
(A) CM area quantification in LV sections. Scale bar, 30 mm.
(B) Trichrome staining and quantification of fibrotic area. Scale bar, 400 mm (top), 40 mm (bottom).
(C) TUNEL staining of heart sections with quantification of TUNEL-positive nuclei. Scale bar, 20 mm.
(D) PECAM-1 immunofluorescence staining of LV sections with quantification of myocardial capillary density. HPF, 4003 high-powered field. Scale bar, 30 mm.
For (A–D) n = 3–4, 4 week time point, *p < 0.05 versus sham veh, #p < 0.05 versus TAC veh. Data shown as mean ± SEM.(Figure 4D) typically seen after 4 weeks of TAC (Sano et al., 2007;
Song et al., 2010).
BET Inhibition Suppresses a Pathologic Cardiac Gene
Expression Program In Vivo
Using the TAC model, we performed detailed transcriptional
analysis in three groups (sham vehicle, TAC vehicle, and TAC-JQ1) at three time points (Figure 5A): 3 days (to reflect early
events that occur prior to the onset of hypertrophy), 11 days
(established hypertrophy), and 28 days (advanced pathologic re-
modeling with signs of HF). Unsupervised hierarchical clustering
revealed that the TAC-veh group had a distinct GEP signature
that evolved with time when compared to the sham-veh group
(Figure 5B). In contrast, TAC-JQ1 clustered with the sham groupCell 154, 569–582, August 1, 2013 ª2013 Elsevier Inc. 575
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and displayed no significant temporal change despite contin-
uous exposure to TAC (Figure 5B). Hence, JQ1 treatment sup-
pressed the evolution of a broad pathologic gene expression
program in the heart, with effects evident as early as 3 days
post-TAC. Similar to our studies in isolated CMs (Figure 2), global
GEP analysis revealed threemajor clusters: genes that were TAC
inducible and suppressed by JQ1, those that were TAC inducible
and unaffected by JQ1, and those that were TAC suppressed
and unaffected by JQ1. A representative heatmap of genes
(selected for the highest magnitude of TAC-mediated change)
highlights each of these three clusters (Figure 5C; full list of differ-
ential transcripts provided in Table S2). TAC did not significantly
alter myocardial expression of Brd2, Brd3, or Brd4 (Figure S4A).
To visualize the global transcriptional effects of TAC and BET
bromodomain inhibition in the model over time, we performed
gene expression dynamics inspector (GEDI) analysis (Eichler
et al., 2003). Although the sham mosaic remained temporally
invariant, TAC resulted in progressive induction of gene clusters
over time, indicated by increased signal in numerous tiles within
the mosaic (Figure 5D). BET bromodomain inhibition disrupted
the temporal evolution of this TAC-induced, pathologic tran-
scriptional program with a mosaic signature that more closely
resembled the sham group (Figure 5D). A volcano plot showing
fold change effect of TAC-JQ1 versus TAC vehicle (shades of
blue) on the set of all genes upregulated at any time point by
TAC (shades of red) is shown in Figure 5E. These data illustrate
the potent and statistically significant effects of JQ1 in suppress-
ing TAC-mediated gene induction. Additionally, comparison of
fold change effect of TAC-JQ1 versus sham vehicle (shades of
blue) on the set of all genes upregulated at any time point by
TAC (shades of red) shows that JQ1 administration reversed
TAC-mediated gene induction to levels similar to those in the
sham-treated hearts (Figure S4B). Functional pathway analysis
of TAC-inducible transcripts that were suppressed by JQ1
showed enrichment for key biological processes involved in
pathologic myocardial remodeling and HF progression in vivo
(Figure 5F) (Song et al., 2012; Zhao et al., 2004). Importantly,
these functional terms aligned with the data from isolated
NRVM (Figure 2D) and represent pathologic processes univer-
sally observed in advanced human HF (Hannenhalli et al., 2006).
Given the broad effects on myocardial gene expression seen
with JQ1, we hypothesized that BETs enable pathologic gene in-
duction via their ability to coordinately coactivate multiple TF
pathways in vivo. Using gene set enrichment analysis (GSEA)
(Subramanian et al., 2005), we compared our set of TAC-induc-Figure 5. BETs Coactivate a Broad, but Specific Transcriptional Progr
(A) Protocol for GEP experiment.
(B) Unsupervised hierarchical clustering of GEPs.
(C) Heatmap of selected genes. Full list of DE genes in Table S2.
(D) GEDI plots showing temporal evolution of gene clusters.
(E) Volcano plot showing fold change effect of TAC+JQ1 versus TAC veh (shades
(shades of red). Progression from lighter to darker shading represents increasing
(F) DAVID analysis of genes that were TAC-induced and JQ1-reversed. FDR < 5
(G) GSEA for TAC veh and TAC-JQ1 against three independent GEPs derived from
in vivo: Calcineurin-NFAT (driven by a constitutively active Calcineurin-A (CnA) tra
2012] and transgenic GATA4 overexpression [Heineke et al., 2007]). FWER p < 0
three time points. Plots shown for 28 day time point. Data shown as mean ± SEM
See also Figure S4 and Table S2.ible genes that were suppressed by BET inhibition, against
compendia of TF signatures. Specifically, we studied the Broad
Institute Molecular Signatures Database C3 motif gene sets (Xie
et al., 2005), as well as three functional, in vivo signatures of CM-
specific transcriptional effectors: Calcineurin-NFAT (Bousette
et al., 2010), NFkB (Maier et al., 2012), and GATA4 (Heineke
et al., 2007). These analyses revealed that the TAC-induced
gene expression profile was positively enriched for IRF and
ETS consensus binding motifs (family-wise error rate [FWER]
p < 0.0001), as well as for myocardial signatures that result
from Calcineurin-A, NFkB, and GATA4 activation (Figure 5G).
Conversely, the effect of JQ1 demonstrated strong negative
enrichment for these same TF signatures (Figure 5G; FWER
p < 0.0001 for IRF and ETS motifs). In contrast, although TAC
was strongly correlated with both c-Myc and E2F signatures,
there was no significant correlation between c-Myc/E2F and
JQ1 effect at any time point (Figure S4C). Consistent with our
NRVM studies, we also found that JQ1 had no effect on TAC-
mediated induction of Myc expression in vivo (Figure S4D).
Hence, the GSEA data support a model in which BET bromodo-
mains facilitate gene induction via coactivation of specific
myocardial TF networks.
We next compared the set of TAC-inducible genes that were
suppressed by JQ1 against validated gene expression profiles
of advanced nonischemic and ischemic HF in humans (Hannen-
halli et al., 2006). This analysis demonstrated that targets of BETs
in the mouse TAC model overlapped in a statistically significant
manner with the set of genes induced in human HF (Figure S4E;
c2 < 5 3 1014). Interestingly, the vast majority (89%) of these
targets were common to both ischemic and nonischemic human
HF (Figure S4F). Thus, inasmuch as the gene expression profiles
of mice subjected to TAC overlap with that of advanced HF in a
human cohort, we found the principal transcriptional targets of
BET bromodomains in mice were also relevant in human
disease.
BET Bromodomain Inhibition Abrogates Transcriptional
Pause Release Genome wide during Pathologic
Hypertrophy In Vivo
To establish the mechanism by which BET bromodomain inhibi-
tion impairs global transactivation of pathologic transcriptional
programs concomitantly activated during pressure overload,
we performed ChIP coupled with high-throughput genome
sequencing (ChIP-seq) on heart tissue from mice subjected to
sham versus TAC surgery, with and without JQ1 treatment. Foram in the Heart during TAC
of blue) on all genes upregulated at any time point by TAC-veh versus sham veh
time (3, 11, and 28 days).
% considered statistically significant.
CM-specific activation of canonical prohypertrophic transcriptional effectors
nsgene [Bousette et al., 2010], NFkB driven by an IKK2 transgene [Maier et al.,
.250 represents statistically significant enrichment. Data representative for all
.
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heart tissue ChIP-seq, a 4 day time point was chosen to capture
changes in chromatin state that occur during the initial phase of
hypertrophic growth in the TAC model (3–7 days). Experi-
mental data obtained for BRD4 and Pol II were integrated with
publicly available data fromBing Ren and colleagues, which pro-
vided epigenomic landscapes for murine cardiac euchromatin
(Shen et al., 2012). Genome-wide data for Pol II enrichment in
our sham operated mice demonstrated excellent statistical
agreement with Pol II enrichment curated from the literature
(R2 = 0.65; Figures S5A and S5B).
First, we determined the sites of genome-wide localization of
BRD4 in the murine heart. Strong enrichment was observed at
promoter regions of actively transcribed genes, as identified by
enrichment for histone 3 lysine 4 trimethylation (H3K4me3) and
Pol II (Figure 6A). Rank ordering of all transcriptionally active pro-
moters by Pol II occupancy identified global binding of BRD4 at
sites of transcriptional initiation. Recently, BET bromodomains
have also been shown to bind to enhancer elements in the
eukaryotic genome (Love´n et al., 2013; Zhang et al., 2012). Bind-
ing of BRD4 to enhancer elements was assessed by rank-
ordering regions of enrichment for histone 3 lysine 27 acetylation
(H3K27ac) and comparing BRD4 enrichment to that of P300, a
known enhancer factor of functional significance in cardiac
hypertrophy (Wei et al., 2008). Importantly, BRD4 binds to the
vast majority of active enhancers in the murine cardiac genome
(Figure 6B).
BRD4, through its C-terminal domain (CTD), physically associ-
ates with and activates CDK9 (Bisgrove et al., 2007; Jang et al.,
2005; Yang et al., 2005), a core component of the P-TEFb com-
plex, which functions as an elongation-promoting Pol II CTD
kinase (Peterlin and Price, 2006). Hyperactivation of P-TEFb
and consequent increases in global transcription are considered
a hallmark of pathologic cardiac hypertrophy in multiple systems
(Espinoza-Derout et al., 2009; Sano et al., 2002; Yoshikawa et al.,
2012). Inhibition of CDK9 function in NRVM has been shown to
attenuate endothelin-1-mediated hypertrophy in vitro (Sano
et al., 2002). These observations provided us with a rationale
to explore the effect of BET bromodomain inhibition on transcrip-
tional elongation in the TAC model in vivo.
BET bromodomain inhibition by JQ1 has been shown to
displace BRD4 and P-TEFb from chromatin leading to a
decrease in Pol II elongation at active genes (Love´n et al.,
2013). Gene-specific effects on Pol II occupancy were explored
at canonical mediators and effectors of pathologic cardiac re-
modeling. As shown for representative genes in Figures 6C
and 6D, sham-treated hearts feature a pronounced Pol II enrich-
ment peak at the TSS of Ctgf and Serpine1 (SerpinE1/PAI-1),
with only modest evidence of downstream elongation (gray
wiggle plots). Following TAC, transcriptional activation (as
shown in Figure 5C and Table S2) was accompanied by a shift
in the distribution of gene bound Pol II toward a higher relative
occupancy in the elongating gene body region (black wiggle
plots; Figures 6C and 6D). BET bromodomain inhibitionmarkedly
attenuated Pol II occupancy in the elongating region, leading to
higher relative Pol II occupancy at the TSS initiation site (red
wiggle plots), consistent with its ability to attenuate transcription
elongation. Additional representative Pol II enrichment plots for
the Ace, Bgn, Thbs1, and Xirp2 loci are shown in Figure S5C.578 Cell 154, 569–582, August 1, 2013 ª2013 Elsevier Inc.Global effects of BET bromodomain inhibition on initiation and
elongation were further examined by calculating the Pol II trav-
eling ratio at all actively transcribed genes and on the subset of
genes induced by TAC. Traveling ratio is a validated measure
of transcriptional pause release that compares promoter and
elongating gene body occupancy levels of Pol II to quantify the
ratio of paused to elongating Pol II (Lin et al., 2012; Wade and
Struhl, 2008). BET bromodomain inhibition of TAC-treated hearts
led to a higher ratio of promoter to elongating gene body Pol II
compared to TAC at all active genes (Figure 6E) and at TAC-
induced genes that were reversed by JQ1 (Figure 6F). A meta-
gene analysis of Pol II enrichment among actively transcribed
genes verified the change in the ratio of promoter to elongating
gene body Pol II by JQ1 (Figure S5D). The effects of JQ1 on tran-
scriptional elongation in the TAC model were reproduced in an
independent in vivo biological replicate, as shown in Figure S5E.
Given the high variability in dynamic range between heart
tissue samples ChIP-seq (Figure S5F) and the relative nature of
metrics such as the traveling ratio, we examined global levels
of initiating and elongating Pol II to further quantify the effects
of BET bromodomain inhibition. We observed a specific
decrease in the elongation-specific serine 2 Pol II phosphoform
(Ser2P) upon JQ1 treatment (Figure 6G) with little change to the
initiation-specific serine 5Pol II phosphoform (Ser5P) (Figure 6H).
JQ1-mediated suppression of Pol II Ser2P abundance was reca-
pitulated in the in vitro NRVM model (Figure S5G). Interestingly,
we also observed significant upregulation of the P-TEFb inhibi-
tory protein HEXIM1 (Espinoza-Derout et al., 2009; Peterlin and
Price, 2006; Yoshikawa et al., 2012) during JQ1 treatment, sug-
gesting an additional mechanism by which BET bromodomain
inhibition may inhibit transcriptional elongation (Figures S5H–
S5K). We conclude that transcriptional elongation is an impor-
tant mechanism by which BET bromodomain inhibition attenu-
ates gene expression programs activated during pathologic
cardiac hypertrophy.
DISCUSSION
Our current work implicates BET bromodomain reader proteins
as essential transcriptional coactivators of a pathologic gene
expression program that drives CM hypertrophy and HF pro-
gression. Gene-expression profiling and ChIP-seq studies reveal
that BET proteins function, in part, by promoting transcriptional
pause release during pathologic stress. In broadest terms, the
data presented here directly implicate epigenetic readers in car-
diac biology and identify BET bromodomain proteins as potential
therapeutic targets in heart disease.
Pathologic cardiac hypertrophy ensues by a collaborative
interplay between master regulatory TFs and dynamic changes
in chromatin structure (Lee and Young, 2013). TFs including
NFAT, GATA4, and NFkB (Hill and Olson, 2008; Maier et al.,
2012; van Berlo et al., 2011), as well as histone modifying en-
zymes such as EP300 and HDAC2 (Trivedi et al., 2007; Wei
et al., 2008; Zhang et al., 2002) activate a CM gene expression
program that results in cellular dysfunction. Dynamic and global
changes in histone 3 lysine 9 acetylation, a chromatin mark for
gene promoters and enhancers, have been observed genome-
wide in the adult mouse heart after pressure overload (Sayed
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Figure 6. BET bromodomain Inhibition Abrogates Transcriptional
Pause Release Genome wide in Pathologic Hypertrophy
(A) Heatmap of Pol II (black), H3K4me3 (orange), and BRD4 (red) levels at
active promoters ranked by Pol II levels in sham-treated heart samples. Each
row shows ±5 kb centered on H3K4me3 peak. Rows ordered by average Pol II
at the promoter.
(B) Heatmap of H3K27ac (green), P300 (blue), and BRD4 (red) levels at active
enhancers ranked by H3K27ac levels in adult heart. Each row shows ±5 kb
centered on H3K27ac peak. Rows ordered by amount of H3K27ac at
enhancer. Color scaled intensities of (A) and (B) are in units of reads per million
per base pair (rpm/bp).et al., 2013). Despite these fundamental observations, the medi-
ators in the heart that link the activity of master regulatory TFs
and histone acetylation to Pol II dynamics and global transcrip-
tional anabolism are poorly understood.
Here, we establish that BET bromodomain reader proteins
function critically in chromatin-mediated signal transduction to
Pol II, coactivating pathologic gene expression in the heart.
GSEA reveals that BET inhibition antagonizes multiple TF out-
puts known to be causal in HF pathogenesis including NFAT,
NFkB, and GATA4, suggesting that BET bromodomain proteins
coactivate a broad transcriptional network involving multiple
TFs. Importantly, we find that BET bromodomain proteins do
not directly affect Myc mRNA levels or function in the heart—a
striking contrast to observations in hematopoietic tumors, where
BETs are required for c-Myc expression and activity (Delmore
et al., 2011; Zuber et al., 2011). ChIP-seq analysis reveals that
BRD4 co-occupies active promoters with Pol II (as defined by
H3K4me3) and active gene enhancers (as defined by H3K27ac)
in the adult mouse heart and that cardiac pressure overload in-
duces Pol II pause release and transcriptional elongation within
4 days. BET bromodomain inhibition suppresses transcriptional
pause release during pressure overload in vivo and attenuates
expression of the pathologic HF gene program. Together, these
data demonstrate that BET bromodomain reader proteins are
indispensable coactivators in pathologic gene expression in
the heart that function, in part, through their ability to promote
Pol II pause release and transcriptional elongation.
Activation of the P-TEFb complex, a central effector of pause
release and transcriptional elongation (Lee and Young, 2013),
has been observed in pathologic cardiac hypertrophy (Sano
et al., 2002). Previous studies in NIH 3T3 cells and macrophages
have demonstrated that BRD4 interacts with P-TEFb and facili-
tates stimulus-coupled recruitment of P-TEFb to target pro-
moters (Hargreaves et al., 2009; Patel et al., 2013). Activity of
CDK9, a core constituent of the P-TEFb complex, is also
increased during hypertrophic stress and is required for
agonist-induced hypertrophy in NRVM (Sano et al., 2002). CM-
specific overexpression of the CDK9-activating protein CyclinT1
results in cardiac hypertrophy in vivo (Sano et al., 2007). In addi-
tion, deficiency of HEXIM-1, a nuclear protein that sequesters
the P-TEFb in an inactive complex, has been shown to potentiate
pathologic hypertrophy in vivo (Espinoza-Derout et al., 2009). In
our studies, localization of BRD4 with promoter-enhancer(C and D) Gene tracks at (C) Ctgf and (D) Serpine1 gene in heart. BRD4 (red) is
from sham-treated hearts. H3K27ac (green) and H3K4me3 (orange) derived
from published landscapes of wild-type mouse hearts (Shen et al., 2012) that
are age/sex/strain-matched to our sham-treated hearts. Pol II are from either
sham (gray), TAC (black), or TAC+JQ1-treated (red) heart. x axis shows
genomic position. y axis shows ChIP-seq occupancy (rpm/bp).
(E and F) Empirical cumulative distribution plots of Pol II traveling ratios (TR)
(Rahl et al., 2010) for genes that are transcriptionally active in either sham or
TAC-treated hearts (E) and genes that are TAC induced and reversed by JQ1
(F). Differences in TR distribution between TAC and TAC+JQ1-treated hearts
are statistically significant (*** Welch’s two-tailed t test, p < 2 3 1016).
(G andH)Western blots with densitometry of heart tissue nuclear extracts from
sham, TAC, and TAC+JQ1-treated hearts for total Pol II or indicated phos-
phoforms (n = 3; #p < 0.05 versus TAC veh). Data shown as mean ± SEM. See
also Figure S5 and Table S3.
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elements and the suppression of pause release with BET bromo-
domain inhibition in the TACmodel (Figure 6) suggest BETs facil-
itate pause release at these gene loci. The robust induction of
HEXIM1 expression we observed following BET bromodomain
inhibition (Figures S5H–S5K) may also serve to suppress
P-TEFb activity and reduce Pol II pause release. Concordant re-
ductions in Ser2 phosphorylation of the Pol II CTD (Figure 6G and
S5G), a specific target of the P-TEFb complex, both in vitro and
in vivo, support these mechanisms of action. Defining the extent
to which BETs alter transcriptional elongation through direct in-
teractions with components of the P-TEFb complex (Bisgrove
et al., 2007) or regulation of HEXIM-1 expression represent
important avenues of future investigation.
Although evidence presented here does implicate BETs in the
regulation of P-TEFb function and Pol II pause release during
TAC, we cannot exclude additional effects of BET bromodo-
mains on Pol II initiation at specific gene promoters. Consistent
with our findings, other work has previously identified that Pol
II pause release is a dominant mechanism for gene induction in
both the developing heart and in the adult mouse heart during
pressure overload, with de novo Pol II recruitment occurring at
only 5% of induced genes in the TAC model (Sayed et al.,
2013). Potential roles for BET bromodomain proteins in locus-
specific Pol II initiation in the heart, or in other aspects of
mRNA processing, are the subject of ongoing research by our
group. Furthermore, the very recent discovery of asymmetrically
loaded BRD4 on a critical subset of state-specific enhancers
termed superenhancers (Love´n et al., 2013) raises the possibility
that such superenhancers might also be active in the stressed
myocardium and contribute to BET target specificity.
HF is known to progress via pathologic crosstalk between
CMs and cardiac fibroblasts (van Berlo et al., 2013). Although
the TAC model of HF provides a relatively focal stress to the
heart, and JQ1 attenuates pathologic remodeling without effects
on blood pressure or hemodynamic load (Figures S3C and S3D),
we recognize that BET bromodomain inhibition in vivo may act
on cardiac fibroblasts and other cell types that populate the
stressed myocardium, in addition to the observed effects on
CMs. We show here that BET bromodomain inhibition or Brd4
knockdown in isolated NRVM both attenuate pathologic CM
hypertrophy in vitro (Figure 1). In addition, we find that Brd4 is
the highest expressed BET gene in isolated CMs and in adult
heart tissue. These data identify a cell-autonomous role for
BRD4 in CMs in vitro and suggest that this protein might be an
important target of BET bromodomain inhibitors in the heart
in vivo. Future studies using cell type and temporally restricted
gene deletion of Brd4 and other BET family members in adult
mice will help annotate their gene- and tissue-specific functions
in experimental models of HF.
In conclusion, this study implicates a family of conserved
epigenetic reader proteins as essential components of the tran-
scriptional machinery that drives pathologic cardiac remodeling
andHF. BET bromodomain proteins function asmaster regulato-
ry TF coactivators that regulate pathologic pause release in the
failing heart. The chemical biological approach leveraged here
in rodent models of pathologic hypertrophy and HF provides a
rationale for developing drug-like BET bromodomain inhibitors
as investigational therapeutic agents in heart disease.580 Cell 154, 569–582, August 1, 2013 ª2013 Elsevier Inc.EXPERIMENTAL PROCEDURES
Animal Models
All protocols concerning animal use were approved by the Institutional Animal
Care and Use Committee at Case Western Reserve University and conducted
in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
All models were conducted in C57Bl/6J mice (Jackson Laboratories), which
were maintained in a pathogen-free facility with standard light/dark cycling
and access to food and water ad libitum.Human Samples
LV samples from healthy human hearts were obtained as described
(Hannenhalli et al., 2006; Margulies et al., 2005) in accordance with the Inves-
tigation Review Committee at the Hospital of the University of Pennsylvania,
Philadelphia, PA. Nuclear protein was extracted using the NE-Per kit (Thermo
Scientific, 78833) according to manufacturer’s instructions. Gene expression
profiles from left ventricles obtained from nonfailing versus failing human
hearts were curated from a published data set (Hannenhalli et al., 2006).Statistical Analysis
Data are reported as mean ± standard error. The statistical methods used in
analysis of microarray and ChIP-seq data are detailed separately. Comparison
of means between two groupswas analyzed using a two-tailed Student’s t test
with Bonferroni correction for multiple comparisons. For all analyses, p
values < 0.05 were considered significant.ACCESSION NUMBERS
The GEO accession number for the ChIP-seq, mouse microarray, and rat
microarray data is GSE48112. The GEO accession numbers for the individual
GEO series corresponding to the ChIP-seq, mouse microarray, and rat micro-
array are GSE46668 (ChIP-seq), GSE48110 (mouse heart), and GSE48111
(NRVM).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, three tables, and four movies and can be found with this article online
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